Though the long range outlook in any phase of the treatment of coronary artery disease is necessarily colored by the inherent progressive trend of an essentially degenerative process, with all of its unpredictable proclivities, nevertheless a favorable outcome could reasonably be anticipated in about 80 per cent of well managed myocardial infarctions following coronary occlusion. It now appears that with the newer developments in anticoagulant therapy, there may be justification for a revision of the philosophy of treatment by adopting the more positive program of management offered by Dicumarol (3,3'-methylene-bis- [4-hydroxycoumarin] ) in addition to the established methods of control. In the treatment of coronary artery disease in general, the following important considerations necessarily influence the symptoms and signs as well as the prognosis and therapeutic response: (1) the type of coronary syndrome presented, whether angina pectoris, acute coronary insufficiency or actual occlusion; (2) the presence and extent of any ensuing